Omeros (NASDAQ:OMER) Announces Quarterly Earnings Results, Beats Expectations By $0.17 EPS

Omeros (NASDAQ:OMER) released its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.17, RTT News reports. During the same quarter in the previous year, the company posted ($0.15) EPS.

Omeros Trading Down 3.0 %

Shares of NASDAQ:OMER opened at $8.22 on Tuesday. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60. The company has a market capitalization of $476.35 million, a price-to-earnings ratio of -3.56 and a beta of 2.03. The firm’s 50-day moving average is $8.66 and its 200 day moving average is $7.58.

Analysts Set New Price Targets

Several analysts have recently issued reports on OMER shares. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Friday, January 17th. D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday. Finally, StockNews.com lowered Omeros from a “hold” rating to a “sell” rating in a research note on Friday, March 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Omeros presently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.